

BoxI	Observations where certain claims were found unsearchable (Continuation of item 1 of first sneet)
This inter	national Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.:  because they relate to subject matter not required to be searched by this Authority, namely:  see FURTHER INFORMATION sheet PCT/ISA/210
	Claims Nos.:  1-35 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  See FURTHER INFORMATION sheet PCT/ISA/210
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inter	mational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 35

Claim 35 relates to a method of treatment of the human or animal body by surgery or by therapy/a diagnostic method practised on the human or animal body Rule 39.1(iv). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compound/composition.

Continuation of Box I.2

Claims Nos.: 1-35

The expressions "diseases or conditions where antagonists of alpha-2-adrenoreceptors are indicated to be useful" in claims 1-10, "disorder of the central nervous system" and "lipolytic disorders" in claim 11, "movement disorder" in claim 12, "for use as a selective alpha-2C antagonist" in claim 13 and "mental disorders propagated by stress" in claim 14 may relate to a large number of different disorders and conditions which cannot be clearly defined by these expressions. The claims are in violation with the requirements of Article 6 PCT that claims shall be clear and concise. The search has therefore been limited to the other, more clearly defined, diseases and groups of diseases mentioned in the present claims 11-12 and 14.

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claims is impossible. Consequently, the search has been restricted to:

claims 1-15 related to the compounds of claims 15-32, claims 16, 18-20, 22, 24-29 and 31-32, claim 30 for Z = -CHR8 - (CH2)n and claims 33-34 related to the compounds of claims 16, 18-20, 22, 24-29, 31-32 and claim 30 for Z = -CHR8 - (CH2)n.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



International Application No
P 1 03/00255

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.		
X	DATABASE STN INTERNATIONAL [Online] File CAPLUS, CAPLUS accession no. 1999:246819, Document no. 131:53570; GRIFFITH, RENATE ET AL: "Modeling of adrenoceptor ligand targets based on novel medium- or macro-sized fused nitrogen heterocyclic systems" XP002245426 & Journal of Computer-Aided Molecular Design (1999), 13(1), 69-78, Compound satisfying formula I with alpha2-adrenergic activity; proviso compound in claim 15 abstract	1,3-6, 9-15, 17-22, 33-35		
X	DATABASE STN INTERNATIONAL [Online] File CAPLUS, CAPLUS accession no. 1981:533210, Document no. 95:133210; BOELSING, EKKEHARD ET AL: "Reactions of indole derivatives. XLVI. Stereoselective route to isoeburnamonine" XP002245427 & Chemische Berichte (1981), 114(5), 1932-7, Compounds satisfying formula IC abstract	26,27,30		
X	DATABASE STN INTERNATIONAL [Online] File CAPLUS, CAPLUS accession no. 1978:597770, Document no. 89:197770; POGOSYAN, S. A. ET AL : "Indole derivatives. LX. 1,2,3,4,4a,5,7,8,13b,13c-Decahydro-13H-ben z(g)indolo(2,3-a)indolizines and 1,2,3,4,4a,5,7,8,9,14,14b,14c-dodecahydroi soindolo(1,2-a)indolo(2,3-c)azepines" XP002245428 & Armyanskii Khimicheskii Zhurnal (1978), 31(4), 260-6, Compound satisfying formula IC with analgesic properties abstract	1-6,11, 23,24, 26,27, 30,33-35.		
X .	DATABASE STN INTERNATIONAL [Online] File HCAPLUS, HCAPLUS accession no. 2001:855109, Document no. 137:88229; ABDEL-ZAHER, AHMED O. ET AL: "The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists " XP002245429 & Pharmacological Research (2001), 44(5), 397-409 abstract	1-6, 11-14, 23,24, 33-35		

## INTERNATIONAL SEARCH REPORT

International Application No PC 03/00255

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D455/00 C07D471/04 C07D491/147 C07D495/14 A61K31/55
A61K31/4375 A61P3/06 A61P3/10 A61P9/02 A61P15/10
A61P25/00 A61P25/14 A61P25/16 A61P25/18 A61P25/22

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) I PC  $\,7\,$  C070 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	US 4 686 226 A (HUFF JOEL R ET AL) 11 August 1987 (1987-08-11) column 1, line 7 - line 58 column 2, line 27 - line 35; examples Alfa2-adrenergic antagonists with use as antidepressives and antidiabetics and satisfying claims 1,9 and 10-14	1-35
	EP 0 213 793 A (WYETH JOHN & BROTHER LTD) 11 March 1987 (1987-03-11) abstract; examples column 9, line 23 - line 30; claims Analogous alfa2-adrenergic antagonists with use as, e.g., antidepressives and antidiabetics	1-35

Further documents are listed in the continuation of box C.	X Patent lannly members are listed in amex.		
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	To later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family		
Date of the actual completion of the international search	Date of mailing of the international search report		
25 June 2003	<b>2</b> 1. 07. 2003		
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswljk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer PER RENSTRÖM /EÖ		

# A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61P25/24 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

### **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 492 303 A (MORRISON GLENN CURTIS ET AL) 27 January 1970 (1970-01-27)	1-7, 11-14, 23-35
	column 1, line 24 -column 2, line 20 column 5 -column 9; examples 3-12 Compounds satisfying claims 1-3, 5 and 11-14, for use as central nervous system depressants	
X	EP 0 130 823 A (RICHTER GEDEON VEGYESZET) 9 January 1985 (1985-01-09) Compounds satisfying formuls IC in claim 26, whith pharmacological properties	26,27, 30,33,34
	-/	`

	<u>^</u>
"A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier document but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  "V" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "&" document member of the same patent family
Date of the actual completion of the international search  25 June 2003	Date of mailing of the international search report .
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo ni,  Fax: (+31-70) 340-3016	Authorized officer PER RENSTRÖM /EÖ

### INTERNATIONAL SEARCH REPORT

International Application No P(1997) 03/00255

		P( 1 03	700255
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to daim No.
K	RIKU AANTAA MD: "Alpha2-adrenoceptor antagonists" BAILLIÈRE'S CLINICAL ANAESTHESIOLOGY, vol. 14, no. 2, 2000, pages 285-292, XP002245599 the whole document		1-6, 11-14, 23,24, 33-35
(	GUAY AT ET AL: "Yohimbine treatment of organic erectile dysfunction in a dose-escalation trial."  INT J IMPOT RES., vol. 14, no. 1, February 2002 (2002-02), pages 25-31, XP002245425 the whole document		1-6, 11-14, 23,24, 33-35

## INTERNATIONAL SEARCH REPORT



P I 03/00255

Patent document cited in search report   Publication date   Patent family member(s)   Publication date   Patent family member(s)   Publication date						
EP 0214556 A1 18-03-1987 JP 62111986 A 22-05-1987  EP 0213793 A 11-03-1987 AT 73804 T 15-04-1992 AU 582663 B2 06-04-1989 AU 6080486 A 12-02-1987 CA 1308720 C 13-10-1992 DE 3684384 D1 23-04-1992 DE 3684384 D1 23-04-1992 DK 380286 A, B, 11-02-1987 EP 0213793 A2 11-03-1987 EP 0213793 A2 11-03-1987 ES 2003086 A6 16-10-1988 GB 2178741 A, B 18-02-1987 GR 862077 A1 24-12-1986 HU 45054 A2 30-05-1988 IE 59304 B1 09-02-1994 JP 1955829 C 28-07-1995 JP 6084374 B 26-10-1994 JP 6084374 B 26-10-1994 PT 83154 A, B 01-09-1986 US 4788202 A 29-11-1988 ZA 8605844 A 30-03-1988  US 3492303 A 27-01-1970 NONE  EP 0130823 A 09-01-1985 HU 34974 A2 28-05-1985 CA 1248958 A1 17-01-1989 DK 317284 A 30-12-1984 EP 0130823 A2 09-01-1985 FI 842236 A 30-12-1984 EP 0130823 A2 09-01-1985 FI 842236 A 30-12-1984						
AU 582663 B2 06-04-1989 AU 6080486 A 12-02-1987 CA 1308270 C 13-10-1992 DE 3684384 D1 23-04-1992 DK 380286 A ,B, 11-02-1987 EP 0213793 A2 11-03-1987 ES 2003086 A6 16-10-1988 GB 2178741 A ,B 18-02-1987 GR 862077 A1 24-12-1986 HU 45054 A2 30-05-1988 IE 59304 B1 09-02-1994 JP 1955829 C 28-07-1995 JP 6084374 B 26-10-1994 JP 6084374 B 26-10-1994 PT 83154 A ,B 01-09-1986 US 4788202 A 29-11-1988 ZA 8605844 A 30-03-1988  US 3492303 A 27-01-1970 NONE  EP 0130823 A 09-01-1985 HU 34974 A2 28-05-1985 CA 1248958 A1 17-01-1989- DK 317284 A 30-12-1984 EP 0130823 A2 09-01-1985 FI 84236 A 30-12-1984 JP 60045581 A 12-03-1985	US 4686226	A	11-08-1987	EP	0214556 A1	18-03-1987
EP 0130823 A 09-01-1985 HU 34974 A2 28-05-1985 CA 1248958 A1 17-01-1989 DK 317284 A 30-12-1984 EP 0130823 A2 09-01-1985 FI 842236 A 30-12-1984 JP 60045581 A 12-03-1985	EP 0213793	A	11-03-1987	AU CA DE EP SB GR JP JP KR TUS	582663 B2 6080486 A 1308720 C 3684384 D1 380286 A ,B, 0213793 A2 2003086 A6 2178741 A ,B 862077 A1 45054 A2 59304 B1 1955829 C 6084374 B 62039586 A 9406630 B1 83154 A ,B 4788202 A	06-04-1989 12-02-1987 13-10-1992 23-04-1992 11-02-1987 11-03-1987 16-10-1988 18-02-1987 24-12-1986 30-05-1988 09-02-1994 28-07-1995 26-10-1994 20-02-1987 23-07-1994 01-09-1986 29-11-1988
CA 1248958 A1 17-01-1989 DK 317284 A 30-12-1984 EP 0130823 A2 09-01-1985 FI 842236 A 30-12-1984 JP 60045581 A 12-03-1985	US 3492303	Α	27-01-1970	NONE		
0061-C0-00 W TC2\000	EP 0130823	A	09-01-1985	CA DK EP FI	1248958 A1 317284 A 0130823 A2 842236 A	17-01-1989 30-12-1984 09-01-1985 30-12-1984